We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure coreplatform@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Intravenous (IV) anesthetics were first discovered for their clinical utility in 1656 by Sir Christopher Wren, an architect, physicist, and astronomer at the University of Oxford while using a goosequill to inject opium into a dog to produce sleep [1]. In 1909, Ludwig Burkhardt became the first surgeon to deliberately use IV ether in a 5% solution to sedate patients for head and neck surgery, finding that a higher concentration caused thrombophlebitis and hemolysis, whereas a lower concentration proved too weak a sedative. The first barbiturate hexobarbital was used in 1932, soon being used for over 10 million cases by 1944. In 1989, the first propofol lipid emulsion formulation was launched in the United States, marking the beginning of the modern age of IV sedation pharmacology [2].
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.